Filter Results:
(446)
Show Results For
- All HBS Web
(631)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Show Results For
- All HBS Web
(631)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Sort by
- March 1992 (Revised June 2005)
- Teaching Note
Monsanto's March into Biotechnology (A), Teaching Note
By: Dorothy Leonard-Barton and Alistair D. Williamson
Teaching Note for (9-690-009). View Details
Keywords: Biotechnology Industry
- 1988
- Chapter
Joint Ventures and Collaboration in the Biotechnology Industry
By: Gary P. Pisano, W. Shan and David Teece
- January 2000
- Article
The Tragedy of the Commoners: Biotechnology and its Publics
By: Arthur A. Daemmrich
Keywords: Biotechnology Industry
Daemmrich, Arthur A. "The Tragedy of the Commoners: Biotechnology and its Publics." Nature Biotechnology 18, no. 1 (January 2000): 2–4.
- March 2011
- Case
MorphoSys AG: The Evolution of a Biotechnology Business Model
By: Gary P. Pisano, Ryan Johnson and Carin-Isabel Knoop
In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this profitability not by developing and selling its own drugs, but by licensing access to its proprietary library of human antibodies. Recently,... View Details
Keywords: Business Model; Profit; Intellectual Property; Rights; Risk Management; Digital Platforms; Product Development; Business and Shareholder Relations; Vertical Integration; Biotechnology Industry; Munich
Pisano, Gary P., Ryan Johnson, and Carin-Isabel Knoop. "MorphoSys AG: The Evolution of a Biotechnology Business Model." Harvard Business School Case 611-046, March 2011.
- Article
Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances
By: Josh Lerner, Hilary Shane and Alexander Tsai
Lerner, Josh, Hilary Shane, and Alexander Tsai. "Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances." Journal of Financial Economics 67, no. 3 (March 2003): 411–446. (Earlier versions distributed as HBS Working Paper No. 00-038 and NBER Working Paper No. 7464.)
- Article
Using Equity Participation to Support Exchange: Evidence from the Biotechnology Industry
By: Gary P. Pisano
Pisano, Gary P. "Using Equity Participation to Support Exchange: Evidence from the Biotechnology Industry." Journal of Law, Economics & Organization 5, no. 1 (Spring 1989): 109–126.
- February 2012
- Article
A 'Core Periphery' Framework to Navigate Emerging Market Governments—Qualitative Evidence from a Biotechnology Multinational
By: Prithwiraj Choudhury, James Geraghty and Tarun Khanna
We build on the emerging literature of influence-based models to study how multinational firms can navigate host governments. Our "core-periphery" framework posits that the actions that an MNC takes with actors in what we call the "periphery"—comprised of state,... View Details
Keywords: Emerging Markets; Multinational Firms and Management; Business and Government Relations; Power and Influence; Framework; Biotechnology Industry; Massachusetts; Brazil; China; Costa Rica; France; India
Choudhury, Prithwiraj, James Geraghty, and Tarun Khanna. "A 'Core Periphery' Framework to Navigate Emerging Market Governments—Qualitative Evidence from a Biotechnology Multinational." Global Strategy Journal 2, no. 1 (February 2012): 71–87.
- September 2020
- Case
Minerva 2010: Turbulent Times
By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at... View Details
Wells, John R., and Benjamin Weinstock. "Minerva 2010: Turbulent Times." Harvard Business School Case 721-390, September 2020.
- Article
The Governance of Innovation: Vertical Integration and Collaborative Arrangements in the Biotechnology Industry
By: Gary P. Pisano
Pisano, Gary P. "The Governance of Innovation: Vertical Integration and Collaborative Arrangements in the Biotechnology Industry." Research Policy 20, no. 3 (June 1991): 237–249.
- Article
The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry
By: Josh Lerner and Robert P. Merges
Lerner, Josh, and Robert P. Merges. "The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry." Journal of Industrial Economics 46, no. 2 (June 1998): 125–156. (Special Symposium "Inside the Pin Factory": Empirical Studies Augmented by Manager Interviews.)
- Article
Discontinuities and Senior Management: Assessing the Role of Recognition in Pharmaceutical Firm Response to Biotechnology
By: Rebecca M. Henderson, Sarah Kaplan and Fiona Murray
Henderson, Rebecca M., Sarah Kaplan, and Fiona Murray. "Discontinuities and Senior Management: Assessing the Role of Recognition in Pharmaceutical Firm Response to Biotechnology." Industrial and Corporate Change 12, no. 2 (April 2003).
- 1989
- Chapter
Collaborative Product Development and the Market for Know-How: Strategies and Structures in the Biotechnology Industry
By: Gary P. Pisano and Paul Mang
Keywords: Product Development; Innovation Strategy; Knowledge Management; Industry Structures; Biotechnology Industry
Pisano, Gary P., and Paul Mang. "Collaborative Product Development and the Market for Know-How: Strategies and Structures in the Biotechnology Industry." In Research on Technological Innovation, Management, and Policy. Vol. 4, edited by Richard S. Rosenbloom and Robert A. Burgelman. Greenwich, CT: JAI Press, 1989.
- October 2016 (Revised February 2017)
- Teaching Note
Alvogen
By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Alvogen is an Icelandic pharmaceutical company that makes and sells generic drugs. Founder and CEO Robert Wessman is deciding whether to take on private equity investors willing to buy out all shareholders, merge with a large and publicly-traded US pharmaceutical... View Details
- February 2003
- Article
The Geography of Opportunity: Spatial Heterogeneity in Founding Rates and the Performance of Biotechnology Rirms
Stuart, Toby E., and Olav Sorenson. "The Geography of Opportunity: Spatial Heterogeneity in Founding Rates and the Performance of Biotechnology Rirms." Research Policy 32, no. 2 (February 2003): 229–253.
- July 2013
- Case
Sample6: Innovating to Make Food Safer
By: Robert F. Higgins and Kirsten Kester
Tim Curran, CEO of Sample6, a start-up biotechnology company developing a novel food safety diagnostics platform, must decide how to partner with food industry players. How can he best convince leaders in this mature industry to adopt a new technology and improve food... View Details
Keywords: Data Analytics; Food Safety; Biotechnology; Nutrition; Entrepreneurship; Product; Partners and Partnerships; Food; Technological Innovation; Business Startups; Governing Rules, Regulations, and Reforms; Product Development; Agribusiness; Information Technology; Globalization; Performance Improvement; Safety; Technology Adoption; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; United States; Boston; Massachusetts
Higgins, Robert F., and Kirsten Kester. "Sample6: Innovating to Make Food Safer." Harvard Business School Case 814-014, July 2013.
- September 2020
- Case
Minerva 2020: Clinical Trials
By: John R. Wells and Benjamin Weinstock
In March 2020, Dr. Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Inc. (Minerva), was reviewing the first results of human clinical trials for the company’s novel CAR-T drug therapeutic, one of the first ever to target solid cancer tumors. The results... View Details
Keywords: Biotechnology; Strategic Decision Making; Entrepreneurship; Health Testing and Trials; Decision Choices and Conditions; Strategy
Wells, John R., and Benjamin Weinstock. "Minerva 2020: Clinical Trials." Harvard Business School Case 721-391, September 2020.
- April 2014
- Case
Merrimack Pharmaceuticals, Inc. (A)
By: Amy C. Edmondson, Bethany S. Gerstein and Melissa Valentine
In 2006, Merrimack Pharmaceuticals was a fast-growing biotechnology company. Its leadership team was divided over whether to keep R&D organized in functional departments or transition to interdisciplinary teams. As a small company, Merrimack's R&D organization had... View Details
Keywords: Teamwork; Interdisciplinary Collaboration; R＆D; Biotechnology; Complexity; Innovation Management; Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Biotechnology Industry; Biotechnology Industry
Edmondson, Amy C., Bethany S. Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (A)." Harvard Business School Case 614-063, April 2014.
- January 2018
- Teaching Note
BeiGene
By: Willy Shih and Jimmy Zhang
Teaching Note for HBS No. 618-033. View Details